Amyloid, Tau, and ApoE: Revisiting Hypotheses of Alzheimer's Disease

Bowen Yao; Minglu Kuang; Derrick Feng Jiang; Chihao Xu

doi:10.54254/2753-8818/2024.19396

Article Information

Received: 29 August 2024

Published: 8 January 2025

DOI: https://doi.org/10.54254/2753-8818/2024.19396

Article Type: Research Article

Cite this article

Yao,B.;Kuang,M.;Jiang,D.F.;Xu,C. (2025). Amyloid, Tau, and ApoE: Revisiting Hypotheses of Alzheimer's Disease. Theoretical and Natural Science,73,242-255.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.73

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]World Health Organization. (2023, March 15). Dementia. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/dementia

[2]Alzheimer, A. (1911) ‘Über eigenartige krankheitsfälle des späteren alters’, Zeitschrift für die gesamte Neurologie und Psychiatrie, 4(1), pp. 356–385. doi:10.1007/bf02866241.

[3]Scheltens, P., Blennow, K., Breteler, M. M., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016). Alzheimer's disease. The Lancet, 388(10043), 505-517. https://doi.org/10.1016/S0140-6736(15)01124-1

[4]Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021). Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021. Journal of Prevention of Alzheimer's Disease, 8(3), 371-386. https://doi.org/10.14283/jpad.2021.23

[5]Dubois, B., von Arnim, C. A. F., Burnie, N., Bozeat, S., & Cummings, J. (2023). Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimer's Research & Therapy, 15(1), 175. https://doi.org/10.1186/s13195-023-01314-6

[6]Chang, C. H., Lin, C. H., & Lane, H. Y. (2021). Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. International Journal of Molecular Sciences, 22(5), 2761. https://doi.org/10.3390/ijms22052761

[7]Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., ... Jack, C. R. Jr. (2016). Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & Dementia, 12(3), 292-323. https://doi.org/10.1016/j.jalz.2016.02.002

[8]Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023). The amyloid cascade hypothesis: an updated critical review. Brain : a journal of neurology, 146(10), 3969–3990. https://doi.org/10.1093/brain/awad159

[9]Zhang, Y.-w., Thompson, R., Zhang, H., & Xu, H. (2011). APP processing in Alzheimer's disease. Molecular Brain, 4(1), 3. https://doi.org/10.1186/1756-6606-4-3

[10]Ferrari, C., & Sorbi, S. (2021). The complexity of Alzheimer’s disease: an evolving puzzle. Physiological Reviews, 101(3), 1047-1081. https://doi.org/10.1152/physrev.00015.2020

[11]Kummer, M. P., & Heneka, M. T. (2014). Truncated and modified amyloid-beta species. Alzheimer's Research & Therapy, 6(3), 28. https://doi.org/10.1186/alzrt258

[12]Ono, K., & Watanabe-Nakayama, T. (2021). Aggregation and structure of amyloid β-protein. Neurochemistry International, 151, 105208. https://doi.org/https://doi.org/10.1016/j.neuint.2021.105208

[13]Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019 Jul 19;14:5541-5554. doi: 10.2147/IJN.S200490. PMID: 31410002; PMCID: PMC6650620.

[14]Karran, E., & De Strooper, B. (2022). The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature Reviews Drug Discovery, 21(4), 306-318. https://doi.org/10.1038/s41573-022-00391-w

[15]Gouras, G. K., Olsson, T. T., & Hansson, O. (2015). β-Amyloid peptides and amyloid plaques in Alzheimer's disease. Neurotherapeutics, 12(1), 3-11. https://doi.org/10.1007/s13311-014-0313-y

[16]Watson, D., Castaño, E., Kokjohn, T. A., Kuo, Y. M., Lyubchenko, Y., Pinsky, D., … Roher, A. E. (2005). Physicochemical characteristics of soluble oligomeric Aβ and their pathologic role in Alzheimer’s disease. Neurological Research, 27(8), 869–881. https://doi.org/10.1179/016164105X49436

[17]Di Fede, G., Catania, M., Maderna, E., Ghidoni, R., Benussi, L., Tonoli, E., Giaccone, G., Moda, F., Paterlini, A., Campagnani, I., Sorrentino, S., Colombo, L., Kubis, A., Bistaffa, E., Ghetti, B., & Tagliavini, F. (2018). Molecular subtypes of Alzheimer’s disease. Scientific Reports, 8(1), 3269. https://doi.org/10.1038/s41598-018-21641-1

[18]Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. Arch Neurol. 2008;65(11):1509–1517. doi:10.1001/archneur.65.11.1509

[19]Benilova, I., Karran, E. & De Strooper, B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15, 349–357 (2012). https://doi.org/10.1038/nn.3028

[20]Chen, G.-f., Xu, T.-h., Yan, Y., Zhou, Y.-r., Jiang, Y., Melcher, K., & Xu, H. E. (2017). Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacologica Sinica, 38(9), 1205-1235. https://doi.org/10.1038/aps.2017.28

[21]Kuznetsov, S. A., Rodionov, V. I., Gelfand, V. I., & Rosenblat, V. A. (1981). Microtubule-Associated Protein MAP1 Promotes Microtubule Assembly in Vitro. FEBS Letters, 135(2), 241–244. https://doi.org/10.1016/0014-5793(81)80791-0

[22]Barbaro, M., et al. (2011). Partial Deletion of the NR5A1 (SF1) Gene Detected by Synthetic Probe MLPA in a Patient with XY Gonadal Disorder of Sex Development. Sexual Development, 5(4), 181–187. https://doi.org/10.1159/000328821

[23]Wegmann, S., Eftekharzadeh, B., Tepper, K., Zoltowska, K. M., Bennett, R. E., Dujardin, S., Laskowski, P. R., et al. (2018). Tau Protein Liquid–Liquid Phase Separation Can Initiate Tau Aggregation. The EMBO Journal, 37(7). https://doi.org/10.15252/embj.201798049

[24]DeFelipe, J. (2016, April 28). Phospho-Tau and Cognitive Decline in Alzheimer’s Disease. Commentary: Tau in Physiology and Pathology. Frontiers in Neuroanatomy. https://doi.org/10.3389/fnana.2016.00044

[25]Liu, P.-P., et al. (2019). Author Correction: History and Progress of Hypotheses and Clinical Trials for Alzheimer’s Disease. Signal Transduction and Targeted Therapy, 4(1). https://doi.org/10.1038/s41392-019-0071-8

[26]Morfini, G., et al. (2002). Fast Axonal Transport Misregulation and Alzheimer’s Disease. NeuroMolecular Medicine, 2(2), 089-100. https://doi.org/10.1385/nmm:2:2:089

[27]Rey, N. L., George, S., Steiner, J. A., Madaj, Z., Luk, K. C., Trojanowski, J. Q., Lee, V. M.-Y., et al. (2017). Spread of Aggregates after Olfactory Bulb Injection of α-Synuclein Fibrils Is Associated with Early Neuronal Loss and Is Reduced Long Term. Acta Neuropathologica, 135(1), 65–83. https://doi.org/10.1007/s00401-017-1792-9

[28]Glatz, D. C., Rujescu, D., Tang, Y., Berendt, F. J., Hartmann, A. M., Faltraco, F., Rosenberg, C., et al. (2006). The Alternative Splicing of Tau Exon 10 and Its Regulatory Proteins CLK2 and TRA2-BETA1 Changes in Sporadic Alzheimer’s Disease. Journal of Neurochemistry, 96(3), 635–644. https://doi.org/10.1111/j.1471-4159.2005.03552.x

[29]Ahmed, Z., Cooper, J., Murray, T. K., Garn, K., McNaughton, E., Clarke, H., Parhizkar, S., et al. (2014). A Novel in Vivo Model of Tau Propagation with Rapid and Progressive Neurofibrillary Tangle Pathology: The Pattern of Spread Is Determined by Connectivity, Not Proximity. Acta Neuropathologica, 127(5), 667–683. https://doi.org/10.1007/s00401-014-1254-6

[30]Philbrick, K. L. (2000). Pharmacological Management of Neurological and Psychiatric Disorders. Mayo Clinic Proceedings, 75(5), 544. https://doi.org/10.1016/s0025-6196(11)64236-5

[31]Aronov, S. (2002). Visualization of Translated Tau Protein in the Axons of Neuronal P19 Cells and Characterization of Tau RNP Granules. Journal of Cell Science, 115(19), 3817–3827. https://doi.org/10.1242/jcs.00058

[32]Malm, J., Graff-Radford, N. R., Ishikawa, M., Kristensen, B., Leinonen, V., Mori, E., Owler, B., Tullberg, M., Williams, M., et al. (2013). Influence of Comorbidities in Idiopathic Normal Pressure Hydrocephalus — Research and Clinical Care. Fluids and Barriers of the CNS, 10(1), 22–22. https://doi.org/10.1186/2045-8118-10-22

[33]Liu, S., Zhang, J.-Y., Li, H., Fang, Z., Wang, Q., Deng, H., Gong, C.-X., et al. (2004). Tau Becomes a More Favorable Substrate for GSK-3 When It Is Prephosphorylated by PKA in Rat Brain. Journal of Biological Chemistry, 279(48), 50078–50088. https://doi.org/10.1074/jbc.m406109200

[34]Pardossi-Piquard, R., Yang, S.-P., Kanemoto, S., Gu, Y., Chen, F., Böhm, C., Sevalle, J., et al. (2009). APH1 Polar Transmembrane Residues Regulate the Assembly and Activity of Presenilin Complexes. Journal of Biological Chemistry, 284(24), 16298–16307. https://doi.org/10.1074/jbc.m109.000067

[35]Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y.-A., Duff, K., et al. (2003). Hyperphosphorylation and Aggregation of Tau in Mice Expressing Normal Human Tau Isoforms. Journal of Neurochemistry, 86(3), 582–590. https://doi.org/10.1046/j.1471-4159.2003.01879.x

[36]Iqbal, K., Gong, C.-X., & Liu, F. (2013). Hyperphosphorylation-Induced Tau Oligomers. Frontiers in Neurology. https://doi.org/10.3389/fneur.2013.00112

[37]Liu, M., Sui, D., Dexheimer, T., Hovde, S., Deng, X., Wang, K. W., Lin, H. L. L., et al. (2020). Hyperphosphorylation Renders Tau Prone to Aggregate and to Cause Cell Death. Molecular Neurobiology, 57(11), 4704–4719. https://doi.org/10.1007/s12035-020-02034-w

[38]Weller, J., & Budson, A. (2018). Current Understanding of Alzheimer’s Disease Diagnosis and Treatment. F1000Research, 7(1), 1161. https://doi.org/10.12688/f1000research.14506.1

[39]Lachs, M. S., & Han, S. D. (2015). Age-Associated Financial Vulnerability: An Emerging Public Health Issue. Annals of Internal Medicine, 163(11), 877. https://doi.org/10.7326/m15-0882

[40]Greener, M. (2015). VCJD: 30 Years Later. Progress in Neurology and Psychiatry, 19(3), 28–30. https://doi.org/10.1002/pnp.382

[41]Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, Mechanisms and Therapy. Nature Reviews Neurology, 9(2), 106–118. https://doi.org/10.1038/nrneurol.2012.263

[42]Corder, E., Saunders, A., Strittmatter, W., Schmechel, D., Gaskell, P., Small, G., Roses, A., Haines, J., & Pericak-Vance, M. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261(5123), 921–923. https://doi.org/10.1126/science.8346443

[43]Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics, 7(2), 180–184. https://doi.org/10.1038/ng0694-180

[44]Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010). Genetics of Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 23(4), 213–227. https://doi.org/10.1177/0891988710383571

[45]Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024). Multifaceted roles of APOE in Alzheimer disease. Nature Reviews Neurology, 1–18. https://doi.org/10.1038/s41582-024-00988-2

[46]Yang, L., March, Z. M., Roxan Amanda Stephenson, & Narayan, P. (2023). Apolipoprotein E in lipid metabolism and neurodegenerative disease. Trends in Endocrinology and Metabolism, 34(8), 430–445. https://doi.org/10.1016/j.tem.2023.05.002

[47]Xu, Q. (2006). Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus. Journal of Neuroscience, 26(19), 4985–4994. https://doi.org/10.1523/jneurosci.5476-05.2006

[48]Wennberg, A. M., Tosakulwong, N., Lesnick, T. G., Murray, M. E., Whitwell, J. L., Liesinger, A. M., Petrucelli, L., Boeve, B. F., Parisi, J. E., Knopman, D. S., Petersen, R. C., Dickson, D. W., & Josephs, K. A. (2018). Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 75(11), 1347–1354. https://doi.org/10.1001/jamaneurol.2018.3139

[49]Herz, J., & Chen, Y. (2006). Reelin, lipoprotein receptors and synaptic plasticity. Nature Reviews Neuroscience, 7(11), 850–859. https://doi.org/10.1038/nrn2009

[50]Frieden, C., Wang, H., & Ho, C. M. W. (2017). A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain–domain interactions. Proceedings of the National Academy of Sciences, 114(24), 6292–6297. https://doi.org/10.1073/pnas.1705080114

[51]Chen, Y., Strickland, M. R., Soranno, A., & Holtzman, D. M. (2021). Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. Neuron, 109(2), 205–221. https://doi.org/10.1016/j.neuron.2020.10.008

[52]Kanekiyo, T., Liu, C.-C. ., Shinohara, M., Li, J., & Bu, G. (2012). LRP1 in Brain Vascular Smooth Muscle Cells Mediates Local Clearance of Alzheimer’s Amyloid- . Journal of Neuroscience, 32(46), 16458–16465. https://doi.org/10.1523/jneurosci.3987-12.2012

[53]Hu, J., Liu, C.-C., Chen, X.-F., Zhang, Y., Xu, H., & Bu, G. (2015). Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice. Molecular Neurodegeneration, 10(1). https://doi.org/10.1186/s13024-015-0001-3

[54]Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., Gouras, G. K., & Deierborg, T. (2022). APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases. Molecular Neurodegeneration, 17(1). https://doi.org/10.1186/s13024-022-00566-4

[55]Hatters, D. M., & Howlett, G. J. (2002). The structural basis for amyloid formation by plasma apolipoproteins: a review. European Biophysics Journal, 31(1), 2–8. https://doi.org/10.1007/s002490100172

[56]Hatters, D. M., Zhong, N., Rutenber, E., & Weisgraber, K. H. (2006). Amino-terminal Domain Stability Mediates Apolipoprotein E Aggregation into Neurotoxic Fibrils. Journal of Molecular Biology, 361(5), 932–944. https://doi.org/10.1016/j.jmb.2006.06.080

[57]Liu, C.-C., Murray, M. E., Li, X., Zhao, N., Wang, N., Heckman, M. G., Shue, F., Martens, Y., Li, Y., Raulin, A.-C., Rosenberg, C. L., Doss, S. V., Zhao, J., Wren, M. C., Jia, L., Ren, Y., Ikezu, T. C., Lu, W., Fu, Y., & Caulfield, T. (2021). APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 13(613). https://doi.org/10.1126/scitranslmed.abc9375

[58]Wisniewski, T., & Frangione, B. (1992). Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neuroscience Letters, 135(2), 235–238. https://doi.org/10.1016/0304-3940(92)90444-c

[59]Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., Kim, J., Eimer, W. A., Estus, S., Rebeck, G. William., Weeber, E. J., Bu, G., Yu, C., & LaDu, M. J. (2012). APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 287(50), 41774–41786. https://doi.org/10.1074/jbc.m112.407957

[60]Fagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2002). Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer’s Disease. Neurobiology of Disease, 9(3), 305–318. https://doi.org/10.1006/nbdi.2002.0483

[61]Huang, Y.-W. A., Zhou, B., Wernig, M., & Südhof, T. C. (2017). ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion. Cell, 168(3), 427-441.e21. https://doi.org/10.1016/j.cell.2016.12.044

[62]Mak, A. C. Y., Pullinger, C. R., Tang, L. F., Wong, J. S., Deo, R. C., Schwarz, J.-M., Gugliucci, A., Movsesyan, I., Ishida, B. Y., Chu, C., Poon, A., Kim, P., Stock, E. O., Schaefer, E. J., Asztalos, B. F., Castellano, J. M., Wyss-Coray, T., Duncan, J. L., Miller, B. L., & Kane, J. P. (2014). Effects of the Absence of Apolipoprotein E on Lipoproteins, Neurocognitive Function, and Retinal Function. JAMA Neurology, 71(10), 1228–1236. https://doi.org/10.1001/jamaneurol.2014.2011

[63]Wennberg, A. M., Tosakulwong, N., Lesnick, T. G., Murray, M. E., Whitwell, J. L., Liesinger, A. M., Petrucelli, L., Boeve, B. F., Parisi, J. E., Knopman, D. S., Petersen, R. C., Dickson, D. W., & Josephs, K. A. (2018). Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 75(11), 1347–1354. https://doi.org/10.1001/jamaneurol.2018.3139

[64]Gratuze, M., Jiang, H., Wang, C., Xiong, M., Bao, X., & Holtzman, D. M. (2022). APOE Antibody Inhibits Aβ-Associated Tau Seeding and Spreading in a Mouse Model. Annals of Neurology, 91(6), 847–852. https://doi.org/10.1002/ana.26351

[65]Hou, T.-T., Han, Y.-D., Cong, L., Liu, C.-C., Liang, X.-Y., Xue, F.-Z., & Du, Y.-F. (2020). Apolipoprotein E Facilitates Amyloid-β Oligomer-Induced Tau Phosphorylation. Journal of Alzheimer’s Disease, 74(2), 521–534. https://doi.org/10.3233/jad-190711

[66]Y, S., K, Y., Sa, L., St, S., L, Z., W, L., Rm, T., S, S., Lt, G., Jc, R., G, G., K, W., J, R., G, R., Mb, F., H, J., Pm, S., C, B., Mw, W., & C, S. (2017, September 28). ApoE4 Markedly Exacerbates Tau-Mediated Neurodegeneration in a Mouse Model of Tauopathy. Nature. https://pubmed.ncbi.nlm.nih.gov/28959956/

[67]Hudry, E., Dashkoff, J., Roe, A. D., Takeda, S., Koffie, R. M., Hashimoto, T., Scheel, M., Spires-Jones, T., Arbel-Ornath, M., Betensky, R., Davidson, B. L., & Hyman, B. T. (2013). Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain. Science Translational Medicine, 5(212), 212ra161–212ra161. https://doi.org/10.1126/scitranslmed.3007000

[68]Suidan, G. L., & Ramaswamy, G. (2019). Targeting Apolipoprotein E for Alzheimer’s Disease: An Industry Perspective. International Journal of Molecular Sciences, 20(9), 2161. https://doi.org/10.3390/ijms20092161

[69]TCW, J., Qian, L., Pipalia, N. H., Chao, M. J., Liang, S. A., Shi, Y., Jain, B. R., Bertelsen, S. E., Kapoor, M., Marcora, E., Sikora, E., Andrews, E. J., Martini, A. C., Karch, C. M., Head, E., Holtzman, D. M., Zhang, B., Wang, M., Maxfield, F. R., & Poon, W. W. (2022). Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell, 185(13), 2213-2233.e25. https://doi.org/10.1016/j.cell.2022.05.017

[70]Steele, O. G., Stuart, A. C., Minkley, L., Shaw, K., Bonnar, O., Anderle, S., Penn, A. C., Rusted, J., Serpell, L., Hall, C., & King, S. (2022). A multi‐hit hypothesis for an APOE4 ‐dependent pathophysiological state. European Journal of Neuroscience, 56(9), 5476–5515. https://doi.org/10.1111/ejn.15685

[71]Schmukler, E., Solomon, S., Simonovitch, S., Goldshmit, Y., Wolfson, E., Michaelson, D. M., & Pinkas-Kramarski, R. (2020). Altered mitochondrial dynamics and function in APOE4 -expressing astrocytes. Cell Death & Disease, 11(7), 1–13. https://doi.org/10.1038/s41419-020-02776-4

[72]Mahan, T. E., Wang, C., Bao, X., Choudhury, A., Ulrich, J. D., & Holtzman, D. M. (2022). Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis. Molecular Neurodegeneration, 17(1). https://doi.org/10.1186/s13024-022-00516-0

[73]Wang, C., Xiong, M., Gratuze, M., Bao, X., Shi, Y., Andhey, P. S., Manis, M., Schroeder, C., Yin, Z., Madore, C., Butovsky, O., Artyomov, M., Ulrich, J. D., & Holtzman, D. M. (2021). Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron, 109(10), 1657-1674.e7. https://doi.org/10.1016/j.neuron.2021.03.024

[74]Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., Greco, D. J., Smith, S. T., Tweet, G., Humulock, Z., Zrzavy, T., Conde-Sanroman, P., Gacias, M., Weng, Z., Chen, H., & Tjon, E. (2017). The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity, 47(3), 566-581.e9. https://doi.org/10.1016/j.immuni.2017.08.008

[75]Serrano-Pozo, A., Li, Z., Noori, A., Nguyen, H. N., Mezlini, A., Li, L., Hudry, E., Jackson, R. J., Hyman, B. T., & Das, S. (2021). Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer’s disease. Nature Aging, 1(10), 919–931. https://doi.org/10.1038/s43587-021-00123-6

[76]Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., Rueda, R., Kritskiy, O., Abdurrob, F., Peng, Z., Milo, B., Yu, C. J., Elmsaouri, S., Dey, D., Ko, T., & Yankner, B. A. (2018). APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer’s Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron, 98(6), 1294. https://doi.org/10.1016/j.neuron.2018.06.011

[77]Yin, Z., Rosenzweig, N., Kleemann, K. L., Zhang, X., Brandão, W., Margeta, M. A., Schroeder, C., Sivanathan, K. N., Silveira, S., Gauthier, C., Mallah, D., Pitts, K. M., Durao, A., Herron, S., Shorey, H., Cheng, Y., Barry, J.-L., Krishnan, R. K., Wakelin, S., & Rhee, J. (2023). APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints. Nature Immunology, 24(11), 1839–1853. https://doi.org/10.1038/s41590-023-01627-6

[78]Konings, S. C., Torres-Garcia, L., Martinsson, I., & Gouras, G. K. (2021). Astrocytic and Neuronal Apolipoprotein E Isoforms Differentially Affect Neuronal Excitability. Frontiers in Neuroscience, 15. https://doi.org/10.3389/fnins.2021.734001

[79]Koutsodendris, N., Blumenfeld, J., Agrawal, A., Traglia, M., Grone, B., Zilberter, M., Yip, O., Rao, A., Nelson, M. R., Hao, Y., Thomas, R., Yoon, S. Y., Arriola, P., & Huang, Y. (2023). Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits. Nature Aging. https://doi.org/10.1038/s43587-023-00368-3

[80]Cheng, G. W.-Y., Mok, K. K.-S., Yeung, S. H.-S., Kofler, J., Herrup, K., & Tse, K.-H. (2022). Apolipoprotein E ε4 Mediates Myelin Breakdown by Targeting Oligodendrocytes in Sporadic Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 81(9), 717–730. https://doi.org/10.1093/jnen/nlac054

[81]Blanchard, J. W., Akay, L. A., Davila-Velderrain, J., von Maydell, D., Mathys, H., Davidson, S. M., Effenberger, A., Chen, C.-Y., Maner-Smith, K., Hajjar, I., Ortlund, E. A., Bula, M., Agbas, E., Ng, A., Jiang, X., Kahn, M., Blanco-Duque, C., Lavoie, N., Liu, L., & Reyes, R. (2022). APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature, 611(7937), 769–779. https://doi.org/10.1038/s41586-022-05439-w

[82]Chen, H.-K., Ji, Z.-S., Dodson, S. E., Miranda, R. D., Rosenblum, C. I., Reynolds, I. J., Freedman, S. B., Weisgraber, K. H., Huang, Y., & Mahley, R. W. (2011). Apolipoprotein E4 Domain Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target for Alzheimer Disease. The Journal of Biological Chemistry, 286(7), 5215–5221. https://doi.org/10.1074/jbc.M110.151084

[83]Lee, H., Cho, S., Kim, M.-J., Yeo Jin Park, Cho, E., Yeon Suk Jo, Kim, Y.-S., Jung Yi Lee, Themis Thoudam, Woo, S.-H., Lee, S.-I., Jeon, J., Lee, Y., Suh, B., Jong Hyuk Yoon, Go, Y., Lee, H., & Seo, J. (2023). ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes. Cell Reports, 42(10), 113183–113183. https://doi.org/10.1016/j.celrep.2023.113183

[84]Calvo-Rodriguez, M., Hou, S. S., Snyder, A. C., Kharitonova, E. K., Russ, A. N., Das, S., Fan, Z., Muzikansky, A., Garcia-Alloza, M., Serrano-Pozo, A., Hudry, E., & Bacskai, B. J. (2020). Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer’s disease. Nature Communications, 11(1), 2146. https://doi.org/10.1038/s41467-020-16074-2

[85]Calvo-Rodriguez, M., Hou, S. S., Snyder, A. C., Kharitonova, E. K., Russ, A. N., Das, S., Fan, Z., Muzikansky, A., Garcia-Alloza, M., Serrano-Pozo, A., Hudry, E., & Bacskai, B. J. (2020). Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer’s disease. Nature Communications, 11(1), 2146. https://doi.org/10.1038/s41467-020-16074-2